Allarity Therapeutics (ALLR) Competitors $1.66 -0.20 (-10.75%) Closing price 04:00 PM EasternExtended Trading$1.66 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. VXRT, CRVO, OKYO, ENTX, QNCX, WHWK, ATRA, ABOS, EXOZ, and IMUXShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Vaxart (VXRT), CervoMed (CRVO), OKYO Pharma (OKYO), Entera Bio (ENTX), Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Atara Biotherapeutics (ATRA), Acumen Pharmaceuticals (ABOS), eXoZymes (EXOZ), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Its Competitors Vaxart CervoMed OKYO Pharma Entera Bio Quince Therapeutics Whitehawk Therapeutics Atara Biotherapeutics Acumen Pharmaceuticals eXoZymes Immunic Vaxart (NASDAQ:VXRT) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Which has higher valuation and earnings, VXRT or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than Vaxart. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M1.88-$66.95M-$0.25-1.56Allarity TherapeuticsN/AN/A-$24.51MN/AN/A Do insiders and institutionals have more ownership in VXRT or ALLR? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 2.8% of Vaxart shares are owned by insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is VXRT or ALLR more profitable? Allarity Therapeutics has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Vaxart's return on equity of -91.89% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% Allarity Therapeutics N/A -173.31%-102.57% Does the media refer more to VXRT or ALLR? In the previous week, Vaxart had 4 more articles in the media than Allarity Therapeutics. MarketBeat recorded 6 mentions for Vaxart and 2 mentions for Allarity Therapeutics. Vaxart's average media sentiment score of 0.53 beat Allarity Therapeutics' score of 0.45 indicating that Vaxart is being referred to more favorably in the media. Company Overall Sentiment Vaxart Positive Allarity Therapeutics Neutral Which has more risk and volatility, VXRT or ALLR? Vaxart has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Do analysts recommend VXRT or ALLR? Vaxart currently has a consensus target price of $2.00, suggesting a potential upside of 412.82%. Allarity Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 442.17%. Given Allarity Therapeutics' higher possible upside, analysts clearly believe Allarity Therapeutics is more favorable than Vaxart.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVaxart beats Allarity Therapeutics on 8 of the 11 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.19M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E RatioN/A21.1774.5225.93Price / SalesN/A463.28536.78122.58Price / CashN/A46.6837.5660.44Price / Book1.029.6112.166.29Net Income-$24.51M-$53.29M$3.28B$270.77M7 Day Performance-15.74%0.29%0.98%3.36%1 Month Performance72.93%8.91%7.20%6.41%1 Year Performance-42.36%13.14%63.06%28.26% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics1.9194 of 5 stars$1.66-10.8%$9.00+442.2%-50.9%$27.19MN/A0.0010Short Interest ↑VXRTVaxart2.0328 of 5 stars$0.39+8.3%$2.00+412.8%-58.5%$89.28M$47.40M-1.44120Gap DownCRVOCervoMed3.8242 of 5 stars$9.62+3.2%$23.71+146.5%-41.4%$89.01M$9.74M-3.694Positive NewsAnalyst RevisionOKYOOKYO Pharma2.2101 of 5 stars$2.35+3.1%$7.00+197.9%+108.7%$88.39MN/A0.007Short Interest ↑ENTXEntera Bio1.4935 of 5 stars$1.93-0.5%$10.00+418.1%+3.4%$88.13M$180K-7.4220Positive NewsQNCXQuince Therapeutics3.7211 of 5 stars$1.60+3.9%$8.14+408.9%+115.0%$85.94MN/A-1.4760News CoverageWHWKWhitehawk Therapeutics1.1892 of 5 stars$1.81+2.0%N/AN/A$85.07M$25.98M-30.0840ATRAAtara Biotherapeutics4.5763 of 5 stars$12.05-2.5%$21.00+74.3%+46.3%$84.63M$128.94M-28.02330ABOSAcumen Pharmaceuticals2.9032 of 5 stars$1.36+3.8%$7.00+414.7%-43.7%$82.38MN/A-0.6020EXOZeXoZymes1.2246 of 5 stars$9.70flatN/AN/A$81.36M$70K0.0029Gap DownIMUXImmunic2.4432 of 5 stars$0.82-5.7%$7.50+814.6%-43.9%$80.89MN/A-0.8770Gap Up Related Companies and Tools Related Companies Vaxart Alternatives CervoMed Alternatives OKYO Pharma Alternatives Entera Bio Alternatives Quince Therapeutics Alternatives Whitehawk Therapeutics Alternatives Atara Biotherapeutics Alternatives Acumen Pharmaceuticals Alternatives eXoZymes Alternatives Immunic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts